ITOS — iTeos Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $448.68m
- -$66.75m
- $35.00m
- 56
- 40
- 32
- 37
Annual cashflow statement for iTeos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -38 | 215 | 96.7 | -113 | -134 |
| Depreciation | |||||
| Non-Cash Items | 2.99 | 13.8 | 19.8 | 16.8 | 16.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 9.33 | 284 | -228 | -8.8 | 18.6 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -25.2 | 513 | -111 | -104 | -98.2 |
| Capital Expenditures | -0.377 | -1.24 | -1.06 | -3.06 | -1.66 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -445 | 75.7 | -129 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.377 | -1.24 | -446 | 72.7 | -131 |
| Financing Cash Flow Items | 0.998 | 0.716 | 1.06 | 0 | -0.477 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 340 | 3.66 | 1.98 | 1.11 | 122 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 316 | 512 | -564 | -33.6 | -109 |